Second CRL given to Acacia after ‘continuing deficiencies’

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/david hagerman)
(Image: Getty/david hagerman)

Related tags: Crl, Acacia, Fda, NDA, API, Gmp, Manufacturing

Acacia Pharma receives a second CRL from the US FDA regarding its NDA, after GMP deficiencies during API production were revealed again.

The US Food and Drug Administration (FDA) sent the company a complete response letter (CRL) after ‘continuing deficiencies’ were found at the unnamed contract manufacturer of the active pharmaceutical ingredient (API) of its drug candidate, Barhemsys (amisulpride injection).

Julian Gilbert, CEO of Acacia, said in a statement, that the company is ‘extremely disappointed’ that the amisulpride manufacturer in its application has still not been able to meet the FDA’s required standards.

Barhemsys is a treatment for post-operative nausea and vomiting. Acacia is focused on the development of anti-nausea and vomiting treatments for surgical and cancer patients. It has a further two product candidates that are based on the same API as Barhemsys in its pipeline.

According to Acacia, the FDA found no concerns with the clinical and non-clinical data submitted in the new drug application (NDA) and no further studies nor data analyses will be required for approval.

“As there were no other issues raised with our application, we remain confident that Barhemsys is approvable. We are on track to complete the qualification of an alternative supplier of amisulpride and plan to engage with the FDA as soon as possible to determine the most rapid route to obtaining approval for Barhemsys,”​ Gilbert added.

After its first CRL​, Acacia remained committed to its API manufacturer stating that that contractor had been working collaboratively with the company to resolve the issue.

Related news

Show more

Related products

show more

Integrated Solutions for Accelerated Time to Market

Integrated Solutions for Accelerated Time to Market

Piramal Pharma Solutions | 08-Jun-2021 | Technical / White Paper

Facing capacity constraints? Lock in your program now! With 14 sites around the world providing diverse services ranging from discovery to drug substance...

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Related suppliers

Follow us


View more